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The PI3Kδ isoform is a candidate drug target in leukemia.
Here, we explored its role in Abelson-induced leukemia.
Frank leukemia emerges if the tumor cells have managed
to outwit the immune system. The absence of PI3Kδ
affected both the tumor cells and the NK cells. Abelson-
transformed PI3Kδ-/- cells induced leukemia in RAG2-/-
animals with a significantly increased latency, implicating
PI3Kδ in tumor progression. NK cell function, however,
was also contingent on PI3Kδ. PI3Kδ-/- NK cells failed to
lyse target cells. Capacitance measurements revealed the
underlying defect: in PI3Kδ-/- NK cells lytic granules did not
fuse with the cell membrane. Accordingly, transplanted
leukemic cells killed PI3Kδ-/- animals more rapidly, both in
syngeneic (PI3Kδ-/-) or immunocompromised (RAG2-/-
PI3Kδ-/-) animals. Our observations define a dual function
of PI3Kδ in leukemia and document that the action of
PI3Kδ in the NK compartment is as relevant to the survival
of the mice as the delayed tumor progression.
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